… received pembrolizumab plus axitinib had … pembrolizumab plus axitinib would result in better
outcomes than sunitinib in patients with previously untreated advanced renal-cell carcinoma…

… 5 mg po twice daily in patients with advanced RCC (predominantly clear cell type), 73% of
… to receive pembrolizumab/axitinib (pembrolizumab 200 mg iv every 3 weeks plus axitinib 5 …

… the KEYNOTE-426 trial, we aimed to assess long-term efficacy and safety of pembrolizumab
plus axitinib versus sunitinib monotherapy in patients with advanced renal cell carcinoma. …

… This study showed the combination of axitinib and pembrolizumab is tolerable in patients
with treatment-naive advanced renal cell carcinoma. This outcome contrasts with the toxicities …

… pembrolizumab plus axitinib versus the sunitinib arm. No new safety signals emerged. These
results support pembrolizumab plus axitinib … the benefit of pembrolizumab plus axitinib is …

4500 Background: In the first interim analysis of the randomized, multicenter, open-label,
phase 3 KEYNOTE-426 study (NCT02853331), treatment with pembro + axi significantly …

5001 Background: The randomized, open-label, phase 3 KEYNOTE-426 study (NCT02853331)
demonstrated that pembrolizumab (pembro) + axitinib (axi) significantly improved OS, …

LBA4501 Background: At the first interim analysis of the randomized, open-label, phase 3
KEYNOTE-426 (NCT02853331) study, 1L pembro + axi showed statistically significant OS, …

… Conclusions: Pembro + axi provides benefit in the combined population of pts with IMDC
intermediate or poor risk and in pts whose tumors had sarcomatoid features. The observed …

… Axitinib plus pembrolizumab showed superior overall survival (OS), progression-free … -cell
carcinoma (RCC). We report long-term efficacy and safety of the axitinib/pembrolizumab from …